An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80 6946 to Patients With Advanced Cancer

Trial Profile

An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80 6946 to Patients With Advanced Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Copanlisib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 01 Oct 2016 Status changed from active, no longer recruiting to completed according to the results published in the Annals of Oncology .
    • 01 Oct 2016 Results published in the Annals of Oncology (2016).
    • 16 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top